CONNECT WITH US
HealthTech

HealthTech

Lilly again far surpasses revenue expectations

Endpoints News logo

Published on

Add as a preferred source on Google
Lilly again far surpasses revenue expectations

Eli Lil­ly once again dom­i­nat­ed rev­enue ex­pec­ta­tions, blow­ing past Wall Street’s es­ti­mates by about $2 bil­lion.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ex­cite­ment, anx­i­ety run­ning high for Bio­gen's piv­otal tri­als dur­ing an­a­lyst call October 28, 2026

Pfiz­er In­dia site clo­sure risks ex­ac­er­bat­ing can­cer drug short­ages October 28, 2026

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug

Cit­ing 'safe­ty' and 'free­dom,' HHS will al­low com­pound­ing of cer­tain well­ness pep­tides

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.